Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1489599 | 1.00 | TDP1 (0.55) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL424471 | 1.00 | TDP1 (0.55) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL29673261 | 1.00 | TDP1 (0.55) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL8461991 | 0.98 | TDP1 (0.53) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL9529895 | 0.98 | TDP1 (0.53) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL29733565 | 0.93 | TDP1 (0.48) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL516874 | 0.93 | TDP1 (0.48) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL923829 | 0.93 | TDP1 (0.48) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL4813848 | 0.91 | TDP1 (0.47) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL6654554 | 0.83 | TDP1 (0.70) | TDP1ALDH1A1LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165070-A | Salt and crystal form of 3CL protease small molecule inhibitor, and preparation methods and applications thereof | 北京华益健康药物研究中心 | 2024-06-11 | — | — | CN | claimed |
| CN-111909160-B | Martinib salt compound and preparation method thereof | 苏州鹏旭医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-114942278-B | Analysis method of related substances of Leitemivir intermediate di-D- (+) -di-p-methylbenzoyl tartaric acid ethyl acetate complex | 山东诚创蓝海医药科技有限公司 | 2023-09-08 | — | — | CN | claimed |
| WO-2020224633-A1 | UPADACITINIB SALT COMPOUND AND PREPARATION METHOD THEREFOR | 苏州鹏旭医药科技有限公司 | 2020-11-12 | — | — | WO | claimed |
| CN-111909160-A | Upacatinib salt compound and preparation method thereof | 苏州鹏旭医药科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-111499640-A | Chiral resolution method of piperazinotriazole derivatives | 上海医药工业研究院 | 2020-08-07 | — | — | CN | claimed |
| CN-110818705-A | Salt form and corresponding crystal form of valine benazidine and preparation method thereof | 苏州鹏旭医药科技有限公司 | 2020-02-21 | — | — | CN | claimed |
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | AMOREPACIFIC CORPORATION (KR) | 2019-11-19 | — | — | US | claimed |
| EP-3162793-B1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORP (KR) | 2019-04-10 | — | — | EP | claimed |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2017-11-30 | — | — | US | claimed |
| EP-1149831-B1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER PROD INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | claimed |
| WO-2004056795-A1 | A PROCESS FOR PREPARING DULOXETINE AND INTERMEDIATES FOR USE THEREIN | CIPLA LTD (IN) | 2004-07-08 | — | — | WO | claimed |
| US-20040077712-A1 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1346988-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDRO- BENZOFURAN COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-09-24 | — | — | EP | claimed |
| US-6570018-B2 | Reducing the propanone of the compound with an alkali metal borohydride and cleaving the protecting group in the presence of methanesulfonic acid; n-methyl-d-aspartic acid receptor antagonist; longer shelf life | PFIZER INC | 2003-05-27 | — | — | US | claimed |
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| EP-1149831-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0924188-A1 | Production of 0,0'-diacyltartaric acid crystals | TORAY INDUSTRIES, INC. (JP) | 1999-06-23 | — | — | EP | claimed |
| EP-0530336-B1 | CHIRAL PHOSPHINES | HOFFMANN LA ROCHE (CH) | 1996-03-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | DHCR24, SRR, ACMSD | TDP1 2080/4885ADRB2 1629/4885ADRB1 1561/4885 |
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | CYP4A11, CYP2S1, CYP4B1 | TDP1 2659/4885ADRB2 487/4885ADRB1 203/4885 |
| US-20040077712-A1 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | ALDH1A2, PARK7, DHPS | TDP1 2159/4885ADRB2 687/4885ADRB1 401/4885 |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | SCN3A, KCNH1, CACNA1G | TDP1 1059/4885ADRB2 292/4885ADRB1 277/4885 |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | DHCR24, SRR, ACMSD | TDP1 2080/4885ADRB2 1629/4885ADRB1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.